Rapiblyk (Landiolol) for Injection: A Comprehensive Overview
Rapiblyk, commercially known as landiolol, is an innovative short-acting beta-adrenergic blocker that has garnered attention for its specific applications in cardiac care. As of 2024, Rapiblyk has been officially approved for use in the United States, introducing a new therapeutic option for healthcare providers managing patients with certain cardiovascular conditions. Its efficacy and rapid onset … Read more